Newsroom

< BACK TO NEWSROOM

Select Dynamin References

October 5, 2020

1) Sever S, Altintas MM, Nankoe SR, Ko D, Wei C, Henderson J, Kretzler M, Cohen C, del Re E, Erickson A, Kerjaschki D, Rudensky A, Nikolic N, Reiser J. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. Journal of Clinical Investigation, 2007; 117:2095-2104 (PMID: 17671649)

2) Gu C, Yaddanapudi S, Weins A, Osborn T, Reiser J, Pollak M, Hartwig J, Sever S. Dynamin directly regulates actin cytoskeleton. EMBO J., 2010; 29:3593-3606 (PMID: 20935625)

3) Yaddanapudi S, Altintas MM, Kistler AD, Fernandez I, Möller CC, Wei C, Peev V, Flesche JB, Forst AL, Li J, Patrakka J, Xiao Z, Grahammer F, Schiffer M, Lohmüller T, Reinheckel T, Gu C, Huber TB, Ju W, Bitzer M, Rastaldi MP, Ruiz P, Tryggvason K, Shaw AS, Faul C, Sever S, Reiser J. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. Journal of Clinical Investigation, 2011; 121:3965-80 (PMID: 21911934)

4) Sever S, Chang J, Gu C. Dynamin rings: not just for fission. Traffic, 2013; 14:1194-9 (PMID: 23980695)

5) Gu C, Chang J, Shchedrina VA, Pham VA, Hartwig JH, Suphamungmee W, Lehman W, Hyman BT, Bacskai BJ, Sever S. Regulation of dynamin oligomerization in cells: the role of dynamin-actin interactions and its GTPase activity. Traffic, 2014; 15:819-38 (PMID: 24891099)

6) Lee HW, Khan SQ, Faridi MH, Wei C, Tardi NJ, Altintas MM, Elshabrawy HA, Mangos S, Quick KL, Sever S, Reiser J, Gupta V. A podocyte-based automated screening assay identifies protective small molecules. J Am Soc Nephrol., 2015 (Epub ahead of print) (PMID: 25858967)

7) Schiffer M, Teng B, Gu C, Shchedrina VA, Kasaikina M, Pham VA, Hanke N, Rong S, Gueler F, Schroder P, Tossidou, Park J-K, Staggs L, Haller H, Erschow S, Hilfiker-Kleiner D, Wei C, Chen C, Tardi N, Hakroush S, Selig MK, Vasilyev A, Merscher S, Reiser J and Sever S. Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models. Nature Medicine, 2015; 21(6):601-609 (PMID: 25962121)

8) Muller-Deile J, Teng B, Schenk H, Haller H, Reiser J, Sever S, Schiffer M. Drugs targeting dynamin can restore cytoskeleton and focal adhesions of urinary podocytes derived from patients with nephrotic syndrome. Ann Transl Med. 2016; 4(21):439 (PMID: 27942530)

9) Gu C, Lee HW, Garborcauskas G, Reiser J, Gupta V, Sever S. Dynamin autonomously regulates podocyte focal adhesion maturation, J Am Soc Nephrol., 2016; 28(2):446-451 (PMID: 27432739)

10) Sever S and Schiffer M. Actin dynamics at focal adhesions: a common endpoint and novel therapeutic target for proteinuric kidney diseases. Kidney International, 2018; 93(6): 1298–1307. (PMID: 29678354)

Latest News
Walden Biosciences Announces Virtual Presentation at Canaccord Genuity 41st Annual Growth Conference
Walden Biosciences Launches to Transform the Treatment of Kidney Disease
Select Dynamin References